Literature DB >> 7586248

Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease.

K Robinson1, E L Mayer, D P Miller, R Green, F van Lente, A Gupta, K Kottke-Marchant, S R Savon, J Selhub, S E Nissen.   

Abstract

BACKGROUND: High plasma homocysteine is associated with premature coronary artery disease in men, but the threshold concentration defining this risk and its importance in women and the elderly are unknown. Furthermore, although low B vitamin status increases homocysteine, the link between these vitamins and coronary disease is unclear. METHODS AND
RESULTS: We compared 304 patients with coronary disease with 231 control subjects. Risk factors and concentrations of plasma homocysteine, folate, vitamin B12, and pyridoxal 5'-phosphate were documented. A homocysteine concentration of 14 mumol/L conferred an odds ratio of coronary disease of 4.8 (P < .001), and 5-mumol/L increments across the range of homocysteine conferred an odds ratio of 2.4 (P < .001). Odds ratios of 3.5 in women and of 2.9 in those 65 years or older were seen (P < .05). Homocysteine correlated negatively with all vitamins. Low pyridoxal 5'-phosphate (< 20 nmol/L) was seen in 10% of patients but in only 2% of control subjects (P < .01), yielding an odds ratio of coronary disease adjusted for all risk factors, including high homocysteine, of 4.3 (P < .05).
CONCLUSIONS: Within the range currently considered to be normal, the risk for coronary disease rises with increasing plasma homocysteine regardless of age and sex, with no threshold effect. In addition to a link with homocysteine, low pyridoxal-5'-phosphate confers an independent risk for coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586248     DOI: 10.1161/01.cir.92.10.2825

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research.

Authors:  Richard S Beard; Shawn E Bearden
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-22       Impact factor: 4.733

Review 2.  Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives.

Authors:  Klaus K Witte; Andrew L Clark
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

3.  Homocysteine: the new player in the field of coronary risk.

Authors:  G Montalescot
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

4.  [A young patient with multiple arterial occlusions].

Authors:  C Panzere; A Brieke; B Bräuer; F Eggemann; H M Becker; P Dieterle
Journal:  Med Klin (Munich)       Date:  1998-05-15

5.  Heart attacks and homocysteine.

Authors:  I Graham; R Meleady
Journal:  BMJ       Date:  1996-12-07

6.  Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status.

Authors:  Martha Savaria Morris; Lydia Sakakeeny; Paul F Jacques; Mary Frances Picciano; Jacob Selhub
Journal:  J Nutr       Date:  2009-11-11       Impact factor: 4.798

Review 7.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

8.  Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics.

Authors:  Mabrouka El Oudi; Zied Aouni; Haroun Ouertani; Chakib Mazigh; Salem Machghoul
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

9.  Plasma total homocysteine and macrovascular complications are associated with food and nutrient intake in patients with Type II diabetes mellitus.

Authors:  Namsoo Chang; Ji-Myung Kim; Hyesook Kim; Yong Wook Cho
Journal:  Nutr Res Pract       Date:  2007-06-30       Impact factor: 1.926

10.  Plasma homocysteine in adolescents depends on the interaction between methylenetetrahydrofolate reductase genotype, lipids and folate: a seroepidemiological study.

Authors:  Ruth Gil-Prieto; Valentín Hernández; Beatriz Cano; Manuel Oya; Angel Gil
Journal:  Nutr Metab (Lond)       Date:  2009-10-05       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.